Algorithm for treatment choice in MDS patients after failure of HMA therapy. Algorithm for treatment choice in MDS patients after failure of HMA therapy.

Slides:

Advertisements

Similar presentations

Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.

Advertisements

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

Final Results From a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Sekeres MA.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1 CC-486 (Oral.

Myelodysplastic Syndromes

Azacitidine 75 mg/m2 per day x 7 days q28

Sekeres MA et al. Proc ASH 2015;Abstract 908.

Volume 20, Issue 2, (February 2012)

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Clinical Trials in IBD.

Role of Chemotherapy in the Current Treatment Paradigm for Men With CRPC.

Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome

Progression After Cancer Immunotherapy in Advanced NSCLC

by Timothy P. Hughes, and David M. Ross

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Updates in Management of Atopic Dermatitis From Real Patient Cases

Fenaux P et al. Lancet Oncol 2009;10(3):

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower- Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005.

How I treat elderly patients with myeloma

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Advances in Myeloid Malignancies

Myelodysplastic Syndromes

How Can we Improve Outcomes for the Elderly Patient with AML?

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

What Is Myelodysplastic Syndrome?

MDS: Introduction. Supportive Care in the Treatment of Lower-Risk Myelodysplastic Syndromes.

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Gene Therapy: Past, Present, and Future

CME-Certified 2012 Hematology Tumor Board Series: Practical Solutions to Current Clinical Challenges in B-Cell Lymphoma.

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Blocking VWF platelet binding to treat TTP

When Is Biologic Therapy Appropriate for HS?

When to Start and What to Use

Getting to Grips With the Science of CGRP and Migraine

MYELODYSPLASTIC SYNDROME: prognosis & treatment options

When Is Intrathecal Drug Delivery Appropriate?

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pollyea DA et al. Proc ASCO 2011;Abstract 6505.

New ELN Recommendations

Patient Questions and Expert Answers in Psoriasis:

The Role of Maintenance Therapy in Multiple Myeloma

Managing Anemia in Lower-Risk MDS

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Biology of Blood and Marrow Transplantation

by Alex Aleshin, and Peter L. Greenberg

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

When Is Intrathecal Drug Delivery Appropriate?

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Gregory G. Ginsberg, MD Gastrointestinal Endoscopy

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

by Giovanni Palladini, and Giampaolo Merlini

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Treatment versus Transplant for Challenging Hematologic Disorders

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse:

Timing for HCT Consultation

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001.

How I treat refractory and early relapsed acute myeloid leukemia

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Treatment of Stage III Non-small Cell Lung Cancer

by Lapo Alinari, and Kristie A. Blum

Initial treatment of CLL: integrating biology and functional status

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment by Waleed Ghanima, Bertrand Godeau,

Presentation transcript:

Algorithm for treatment choice in MDS patients after failure of HMA therapy. Algorithm for treatment choice in MDS patients after failure of HMA therapy. Reasoned choice of second- and third-line treatment options after HMA therapy based on clinical and biological characteristics of the patient. In this setting, experimental trials are recommended; the experimental agents indicated in the figure are those evaluated in the highest number of cases. *Off-label use; on-label use of lenalidomide (LEN) only in del5q; thrombopoietin (TPO) mimetics in experimental trials. AZA, azacitidine; chemo, chemotherapy; DAC, decitabine; PS, performance status. Valeria Santini Blood 2019;133:521-529 ©2019 by American Society of Hematology